Replies to post #462158 on Anavex Life Sciences Corp (AVXL)

[kund]

I don't follow SAVA closely, but the market believes in their trials. They are running longer, bigger, better designed trials, unlike what the clown did—running smaller, lousy designed trials in obscure locations in Australia with made-up endpoints, and soon timeline. Ultimately, trial data, the FDA, and the market will decide the company's value. Right now, this POS is at $300 million despite the so-called successful Phase 2b (3) trial, while SAVA is at $1 billion with 2 Phase 3 in progress.